Inhibitory effect of somatostatin-28 on pancreatic polypeptide, glucagon and insulin secretion in normal man.
We have compared the effects of equimolar doses of intravenous somatostatin-28 (SS-28) and somatostatin-14 (SS-14) (250 micrograms and 125 micrograms, respectively) on the secretion of pancreatic polypeptide (PP), glucagon and insulin evoked by a protein-rich meal in normal subjects. Both peptides reduced the fasting plasma levels of these hormones and completely abolished their responses to the alimentary stimulus; in addition, they caused an early decrease of plasma glucose followed by a hyperglycemic phase. As compared to SS-14, SS-28 elicited a longer-lasting inhibition of PP and insulin secretion and displayed greater hypo- and hyperglycemic effects. A somatostatin-like component, similar to SS-28, has been identified in pancreatic extracts as well as in peripheral plasma. Thus, it might be hypothesized that this peptide plays a role in the control of pancreatic hormone release.
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D005215:Fasting; D005502:Food; D005934:Glucagon / Q000378:metabolism*; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007700:Kinetics; D008297:Male; D010191:Pancreatic Polypeptide / Q000378:metabolism*; D013004:Somatostatin; D053561:Somatostatin-28
D001786:Blood Glucose; D007328:Insulin; D013004:Somatostatin; D010191:Pancreatic Polypeptide; D053561:Somatostatin-28; D005934:Glucagon